VCYT

59.13

0.15% -0.09

Handel nachbörslich: 58.80 -0.33 -0.56%

Veracyte Inc (VCYT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$59.22

Offen:

$57.06

24-Stunden-Volumen:

2.01M

Relative Volume:

1.70

Marktkapitalisierung:

$4.72B

Einnahmen:

$541.74M

Nettoeinkommen (Verlust:

$88.01M

KGV:

54.44

EPS:

1.0862

Netto-Cashflow:

$155.34M

1W Leistung:

+3.79%

1M Leistung:

+15.29%

6M Leistung:

+42.24%

1J Leistung:

+144.14%

1-Tages-Spanne:

$57.06

$59.19

1-Wochen-Bereich:

$55.62

$60.82

52-Wochen-Spanne:

$22.61

$60.91

Veracyte Inc Stock (VCYT) Company Profile

Firmenname

Veracyte Inc

Sektor

Healthcare (1092)

Branche

Diagnostics & Research (49)

Telefon

(650) 243-6300

Adresse

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Mitarbeiter

755

Twitter

@veracyte

Nächster Verdiensttermin

2026-07-30

Neueste SEC-Einreichungen

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, NTRA, A

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VCYT Veracyte Inc	59.13	4.73B	541.74M	88.01M	155.34M	1.0862
TMO Thermo Fisher Scientific Inc	532.48	201.86B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	203.83	145.10B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	567.44	45.44B	4.45B	1.10B	1.06B	13.59
NTRA Natera Inc	271.39	38.64B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	131.46	38.44B	7.23B	1.41B	1.09B	4.979

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-13	Eingeleitet	Jefferies	Buy
2025-12-02	Fortgesetzt	Morgan Stanley	Underweight
2025-10-20	Eingeleitet	Canaccord Genuity	Hold
2025-03-20	Eingeleitet	Craig Hallum	Buy
2024-12-05	Herabstufung	Goldman	Buy → Neutral
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-10-16	Eingeleitet	UBS	Buy
2024-10-10	Eingeleitet	Guggenheim	Buy
2024-02-23	Bestätigt	Needham	Buy
2023-01-18	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-07	Eingeleitet	Stephens	Overweight
2021-11-18	Fortgesetzt	Goldman	Buy
2021-06-15	Eingeleitet	Raymond James	Outperform
2021-02-18	Fortgesetzt	Needham	Buy
2021-01-28	Eingeleitet	Truist	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2020-09-09	Eingeleitet	Morgan Stanley	Underweight
2019-07-31	Eingeleitet	Lake Street	Buy
2019-07-02	Eingeleitet	Needham	Buy
2018-11-29	Herabstufung	Janney	Buy → Neutral
2018-10-31	Hochstufung	Janney	Neutral → Buy
2017-11-07	Herabstufung	Janney	Buy → Neutral
2017-11-07	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-08-31	Fortgesetzt	BTIG Research	Buy
2016-11-14	Fortgesetzt	Leerink Partners	Outperform
2015-12-18	Eingeleitet	Cantor Fitzgerald	Buy
2015-06-11	Bestätigt	Leerink Partners	Outperform
2013-11-26	Eingeleitet	William Blair	Outperform

Alle ansehen

Veracyte Inc Aktie (VCYT) Neueste Nachrichten

Jul 16, 2026

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm

Jul 16, 2026

Jul 15, 2026

A Look at Veracyte Inc (VCYT) After 5.1% Gain -- GF Value $38.30 vs Price $59.51 - GuruFocus

Jul 15, 2026

Piper Sandler Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $66 - Moomoo

Jul 15, 2026

Piper Sandler initiates Veracyte stock with overweight rating By Investing.com - Investing.com Nigeria

Jul 15, 2026

Piper Sandler Initiates Veracyte at Overweight With $66 Price Target - marketscreener.com

Jul 15, 2026

VCYT Initiated Coverage by Piper Sandler -- Rating Overweight - GuruFocus

Jul 15, 2026

Jul 14, 2026

CCORF Maintains Veracyte(VCYT.US) With Hold Rating, Raises Target Price to $60 - Moomoo

Jul 14, 2026

VCYT Maintained by Canaccord Genuity -- Price Target Raised to $60 - GuruFocus

Jul 14, 2026

Jul 12, 2026

Here's how much you'd have if you invested $1000 in Veracyte a decade ago - MSN

Jul 12, 2026

Jul 10, 2026

Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Raises Target Price to $47 - Moomoo

Jul 10, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - BioSpace

Jul 10, 2026

Jul 09, 2026

A Look at Veracyte Inc (VCYT) After 5.5% Gain -- GF Value $38.24 vs Price $59.30 - GuruFocus

Jul 09, 2026

VCYT Maintained by Morgan Stanley -- Price Target Raised to $47. - GuruFocus

Jul 09, 2026

Press Release: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo

Jul 09, 2026

St. Pete woman seeks $10M in discrimination lawsuit against employer - Business Observer

Jul 09, 2026

Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView

Jul 09, 2026

Jefferies Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $70 - Moomoo

Jul 09, 2026

Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st

Jul 09, 2026

Jul 08, 2026

Veracyte Inc updates investors on breast cancer test coverage. Nasdaq-listed diagnostics group build - ad-hoc-news.de

Jul 08, 2026

All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy - Yahoo Finance

Jul 08, 2026

Jul 07, 2026

Is Veracyte (VCYT) Fully Valued As Insider Selling And Index Additions Draw Attention? - simplywall.st

Jul 07, 2026

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy - AOL.com

Jul 07, 2026